carbidopa and levodopa tablet

INDICATIONS AND USAGE Carbidopa and levodopa tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.

actavis pharma, inc.

FDA Reported Adverse Reactions
`[1] off label use` `[2] drug ineffective` `[3] fatigue` `[4] nausea` `[5] pain` `[6] headache` `[7] dyspnoea` `[8] diarrhoea` `[9] arthralgia` `[10] pyrexia`

6 years ago

ROUND YELLOW R 539

6 years ago

R 539 ROUND YELLOW

HOW SUPPLIED

CARBIDOPA AND LEVODOPA Tablets, USP are supplied as follows: 10 mg/100 mg — Each dark blue, mottled, round tablet imprinted with on one side and 538 and bisect on the other side contains 10 mg of carbidopa, USP and 100 mg of levodopa, USP and is supplied in bottles of 100 (NDC 0228-2538-10) and 500 (NDC 0228-2538-50). 25 mg/100 mg — Each yellow, mottled, round tablet imprinted with on one side and 539 and bisect on the other side contains 25 mg of carbidopa, USP and 100 mg of levodopa, USP and is supplied in bottles of 100 (NDC 0228-2539-10), 500 (NDC 0228-2539-50) and 1,000 (NDC 0228-2539-96). 25 mg/250 mg — Each light blue, mottled, round tablet imprinted with on one side and 540 and bisect on the other side contains 25 mg of carbidopa, USP and 250 mg of levodopa, USP and is supplied in bottles of 100 (NDC 0228-2540-10), 500 (NDC 0228-2540-50) and 1,000 (NDC 0228-2540-96). Store at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Manufactured by: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054 Rev. B 9/2020 67944b5f-figure-03 67944b5f-figure-04 67944b5f-figure-05

More pills like ROUND R 539

Related Pills

carbidopa 25 MG levodopa 250 MG Oral Tablet

Actavis Pharma, Inc.

carbidopa 25 MG levodopa 100 MG Oral Tablet

American Health Packaging

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site